Genomics applied to the treatment of breast cancer
Metrics: PDF 1238 views | Full Text 1601 views | ?
Diaddin Hamdan1,2, Thi Thuy Nguyen2,3,4, Christophe Leboeuf2,5, Solveig Meles2, Anne Janin2,5,* and Guilhem Bousquet2,6,7,*
1 Hôpital La Porte Verte, Versailles F-78004, France
2 U942, Université Paris-Diderot, INSERM, Paris F-75010, France
3 National Cancer Hospital, Medical Oncology Department 2, Ha Noi 110000, Viet Nam
4 Ha Noi Medical University, Oncology Department, Ha Noi 116001, Viet Nam
5 AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie, Paris F-75010, France
6 AP-HP-Hôpital Avicenne, Service d’Oncologie Médicale, Bobigny F-93000, France
7 Université Paris 13, Leonard de Vinci, Villetaneuse F-93430, France
* These authors contributed equally to this work
Keywords: constitutional genomics; genomics applied to treatment; genomics of breast cancer; molecular and histological classification; tumor heterogeneity
Received: March 18, 2019 Accepted: July 05, 2019 Published: July 30, 2019
Breast cancer remains a major health issue in the world with 1.7 million new cases in 2012 worldwide. It is the second cause of death from cancer in western countries. Genomics have started to modify the treatment of breast cancer, and the developments should become more and more significant, especially in the present era of treatment personalization and with the implementation of new technologies. With molecular signatures, genomics enabled a de-escalation of chemotherapy and personalized treatments of localized forms of estrogen-dependent breast cancers. Genomics can also make a real contribution to constitutional genetics, so as to identify mutations in a panel of candidate genes. In this review, we will discuss the contributions of genomics applied to the treatment of breast cancer, whether already validated contributions or possible future applications linked to research data.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.